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Abstract
Background: The A53T mutation in the a-synuclein gene causes autosomal-dominant Lewy body Parkinson’s
disease (PD). Cultured cell models have linked this mutation to increased cell macroautophagy, although evidence
of enhanced macroautophagy in patients with this mutation has not been assessed.
Objective: To determine whether macroautophagy is increased by the A53T a-synuclein gene mutation in PD
patients and cell models.
Methods: Formalin-fixed paraffin-embedded 10 μm-thick tissue sections from the substantia nigra and anterior
cingulate cortex of two PD patients with the A53T a-synuclein gene mutation were compared with four sporadic
PD cases and four controls obtained from the Sydney Brain Bank. Lewy bodies were isolated from frontal cortex of
a case with late stage PD (recruited from South Australian Brain Bank). Immunohistochemistry was performed for
a-synuclein and the macroautophagy markers autophagy-specific gene (ATG) 5, ATG6/Beclin1 and ATG8/LC3. SH-
SY5Y cells were transfected with wild type or A53T mutant a-synuclein plasmids and observable changes in
macroautophagy marker protein levels assessed using Western blotting.
Results: a-Synuclein immunoreactive neurites and dots were more numerous in patients with A53T mutations
compared with late stage sporadic PD patients, and perinuclear cytoplasmic a-synuclein aggregates were observed
in the a-synuclein A53T gene transfected SH-SY5Y cells compared to wild type transfections. All PD patients (with
or without A53T mutations) had increased immunohistochemical evidence for macroautophagy compared with
controls, and the levels of the ATG5 complex were equally increased in wild type and A53T a-synuclein gene
transfected cells compared to controls.
Conclusion: Despite increased a-synuclein accumulation with A53T mutations, macroautophagy is not increased
above that observed in sporadic patients with PD or in cells transfected with wild type a-synuclein, suggesting
that mutated a-synuclein protein is not removed by macroautophagy.
Keywords: α-synuclein, macroautophagy, Parkinson’s disease
Introduction
Genetic forms of Parkinson’s disease (PD), the most
common neurodegenerative movement disorder affect-
ing the elderly, provide important information on major
cellular abnormalities occurring in sporadic PD and are
now used in relevant models to understand disease
pathogenesis. Missense mutations in (A53T [1], A30P
[2], E46K [3]) or multiplications of [4] the a-synuclein
gene [5,6] occur only rarely in PD patients, however
abnormalities in the cellular processing of a-synuclein
are considered core to PD pathogenesis due to its
abnormal deposition and fibrilisation within the charac-
teristic pathological inclusions of PD [7,8].
The formation of cytoplasmic a-synuclein pathologies
in PD has been attributed to the dysfunction of protein
degradation pathways through the proteasome [9] and/
or lysosomal autophagy [10,11]. The lysosome partici-
pates in three types of autophagy: macroautophagy,
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microautophagy (lysosomes directly engulf cytoplasmic
contents) and chaperone-mediated autophagy (CMA,
receptor-specific recognition for protein transfer into
lysosomes). Macroautophagy sequesters damaged orga-
nelles and unused long-lived proteins in a specialised
autophagic vacuole or autophagosome, which then fuses
with a lysosome. Macroautophagy is the most efficient
autophagic clearance mechanism and the most impor-
tant for organelle clearance in neurons [12].
Autophagy-specific gene (ATG) proteins are used to
assemble autophagosomes within cells. ATG6/Beclin 1
binds with the anti-apoptotic protein Bcl-2 located in
the cytoplasm, and its dislocation from Bcl-2 is essential
for the initiation of autophagosome generation [13].
ATG5 complexes with ATG12, which then interacts
with lipidated ATG8/LC3, indicating autophagic activa-
tion [14]. These processes have been shown to be upre-
gulated in neurons undergoing neurofibrillary
degeneration in Alzheimer’s disease [14]. In contrast,
dysfunctional autophagosomes and reduced ATG7 but
preservation of many other macroautophagy markers
has been described in association with a-synuclein
deposition in dementia with Lewy bodies [15]. In cul-
tured neurons, A53T mutant a-synuclein protein
enhances macroautophagy [16,17], but this has not been
examined in patients with PD.
Materials and methods
Cases
Formalin-fixed paraffin-embedded 10 μm-thick sections
of midbrain and anterior cingulate cortex (an early
affected limbic brain region [7,8]) of two PD patients
with the A53T a-synuclein gene mutation, four sporadic
PD patients and four controls were obtained from the
Sydney Brain Bank following appropriate institutional
approvals (case details are given in Table 1). Similarly
processed sections from the hippocampus of a case with
Alzheimer’s disease were included as positive controls
for the immunohistochemistry [14]. One PD case with
Braak stage 6 was recruited from the South Australian
Brain Bank for the isolation of cortical Lewy bodies, as
previously described [18].
Cell culture and a-synuclein plasmid transfections
SH-SY5Y cells were obtained from ATCC, USA and cul-
tured at 37°C in Dulbecco’s modified eagle media sup-
plemented with 10% fetal bovine serum, 100 U/ml of
penicillin and 100 μg/ml of streptomycin in a humidified
5% CO2 incubator. Cells were transfected using Lipofec-
tamine 2000 with plasmids (kind gifts from P.J. McLean)
expressing GFP-tagged wildtype (WT) a-synuclein or
GFP-tagged A53T mutant (A53T) a-synuclein. Cells
exposed to Lipofectamine 2000 only were used as con-
trols. The transfection rate, cellular morphology and the
amount of proteins of interest were observed at 24 h.
Western blotting
SH-SY5Y cells expressing WT and A53T a-synuclein
were harvested and solubilised with 2X SDS sample buf-
fer (20 mM dithiothreitol, 6% SDS, 0.25 M Tris, pH 6.8,
10% glycerol, 10mMNaF and bromophenol blue) at
approximately 2 × 106-1 × 107 cells per ml. The extracts
were heated in a boiling water bath for 5 min, and then
sonicated with 3-4 bursts of 5-10 sec each, and finally
separated using 4-12.5% SDS-PAGE. Western blotting
was performed using mouse anti-human a-synuclein
IgG (ab6162, Abcam, USA, diluted 1 mg/ml), rabbit
anti-human ATG5 (Abgent, USA, diluted 1:100), rabbit
anti-human ATG6/Beclin 1 (Abgent, USA, diluted 1:60)
and rabbit anti-human ATG8/LC3 (Abgent, USA,
Table 1 Details of the cases examined for morphological observations
Diagnosis Case
No.
Sex (M/
F)
AOD
(y)
PMD
(hr)
Braak PD stage (0-
6)
Density of a-synuclein inclusions in cingulate
ctx
Density of
ATG8/LC3
immunostaining
in cingulate ctx
Control 1 F 64 5 0 None None
2 M 68 11 0 None None
3 M 75 <24 0 None None
4 F 81 17 0 None None
Sporadic
PD
1 F 69 <24 4 None None
2 M 72 <36 5 Mild None
3 M 79 3 5 Moderate Mild
4 F 78 4 6 Severe Moderate
a-Synuclein 1 M 48 27 6 Severe Moderate
A53T PD 2 M 54 <24 6 Severe Moderate
ctx = cortex; No. = Number; AOD = age of death; PMD = post-mortem delay
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diluted 1:1000). Mouse anti-human b-tubulin III
(ab7751, Abcam, USA, diluted 1:1000) was used to
assess equal protein loading. Experiments were repeated
three times.
Immunohistochemistry
Peroxidase immunohistochemistry for a-synuclein
(mouse anti-human a-synuclein, BD Transduction
Laboratories, Lexington, USA, diluted 1:200) and the
macroautophagy markers ATG5 (rabbit anti-human
ATG5, Abgent, USA, diluted 1:50), ATG6/Beclin 1 (rab-
bit anti-human ATG6, Abgent, USA, diluted 1:10) and
ATG8/LC3 (rabbit anti-human ATG8, Abgent, USA,
diluted 1:1000) was performed on the human brain tis-
sue sections (Table 2). Briefly, sections were pre-treated
with 99% formic acid for 3 min and citrate buffer (pH
6.0) for 3 min, and then following primary antibody
incubation, incubated with biotinylated secondary anti-
bodies (Vector, Burlinghame, USA), avidin-biotin com-
plex (Vectastain Elite ABC Kit, Vector, Burlinghame,
USA) and DAB substrate (Sigma, St. Louis, USA) then
counterstained with cresyl violet.
Co-localisation of the macroautophagy markers with
a-synuclein was assessed on adjacent human brain tis-
sue sections, isolated Lewy bodies, as well as on SH-
SY5Y cells expressing WT and A53T a-synuclein that
were fixed using methanol-acetone (3:1) for 15 min.
Briefly, double labelling immunofluorescence was per-
formed with secondary anti-mouse IgG conjugated with
Alexa Fluor 488 (1:500, Molecular Probes, Oregon,
USA) and anti-rabbit IgG conjugated with Alexa Fluor
568 (1:250, Molecular Probes). The cross-reactivity and
specificity of the immunofluorescence was confirmed by
incubating each primary antibody singly with the sec-
ondary antibody solution containing two fluorophores.
Experiments were repeated three times.
Morphological observations
a-Synuclein and macroautophagy markers immunoreac-
tive aggregates and cells were semi-quantified as mild,
moderate or severe in the immunoperoxidase-labeled
brain tissue sections, and the proportion of transfected
SH-SY5Y cells containing a-synuclein-immunopositive
aggregates was counted in five representative fields from
each experiment. The co-localisation of a-synuclein and
macroautophagy markers was examined at
100×magnification using a confocal microscope (Leica
Microsystems Heidelberg GmbH, Germany).
Results
Differences in the amount and type of a-synuclein
aggregates in A53T versus sporadic PD
Both A53T and sporadic PD had moderate to severe
loss of substantia nigra neurons, as previously described
[19]. There were significantly more a-synuclein-immu-
noreactive Lewy neurites (Figure 1A) in the A53T form
of PD compared with sporadic PD (Figure 1B) [19].
These neurites were substantially larger in cases with
A53T mutations (Figure 1A). As expected, there were
more a-synuclein-immunoreactive cortical Lewy bodies
and astrocytes in end-stage (Figure 1C) compared with
earlier-stages of PD (Figure 1D). The relative densities
of a-synuclein-immunoreactive cortical Lewy bodies are
given in Table 1.
Accumulation and localisation of macroautophagy
markers in A53T versus sporadic PD
Consistent with previous studies in dementia with Lewy
bodies [15], there was an increase in ATG8/LC3-immu-
nopositive cortical neurons with increasing pathological
stage of PD, and some glia also had enhanced ATG8/
LC3 expression (Figure 2A). The density of ATG8/LC3-
immunopositive cortical neurons did not differ between
the cases with A53T mutations and those with end-
stage sporadic PD (Figure 2A & Table 1), both of which
had substantial cortical deposition of a-synuclein (see
above). In cases with no cortical deposition of a-synu-
clein (stage 4 PD and controls), no cortical ATG8/LC3
immunoreactive neurons were observed (Figure 2B).
Double labeling of isolated Lewy bodies with antibodies
to a-synuclein and ATG8/LC3 also showed no colocali-
sation (Figure 2C, D). Immunohistochemistry for the
other macroautophagy markers assessed was not signifi-
cantly increased over controls in any of the PD case
assessed (data not shown), similar to that described pre-
viously for cases with dementia with Lewy bodies [15].
Macroautophagy following overexpression of WT or A53T
a-synuclein in SH-SY5Y cells
Approximately 60% of the SH-SY5Y cells transfected
with A53T a-synuclein-GFP plasmids contained a-synu-
clein-immunopositive aggregates (Figure 3A) compared
Table 2 Macroautophagy Markers Tested and Their Dilutions
Macroautophagy Markers Human Brain Tissues (Immunohistochemistry) Cultured Cells (Western blotting)
Atg 5 1:50 1:100
Atg 6/Beclin 1 1:10 1:60
Atg 8/LC3 1:1000 1:1000
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with approximately 30% of those transfected with WT
a-synuclein-GFP plasmids (Figure 3B). These aggregates
did not colocalise with macroautophagy markers (data
not shown). The a-synuclein-immunopositive aggregates
in cells transfected with A53T a-synuclein-GFP plasmids
(Figure 3A) were much larger compared to those in cells
transfected with WT a-synuclein-GFP plasmid (Figure
3B). In addition, transfection with A53T a-synuclein sig-
nificantly reduced cell viability in comparison to WT a-
synuclein transfection (data not shown). When the same
amount of cellular protein was loaded, there were simi-
lar multiple 20~49kDa bands of GFP-tagged a-synuclein
detected in both WT and A53T transfected cells (Figure
3C), as previously reported [9]. Western immunoblot-
ting revealed a significant increase in the macroauto-
phagy marker for the ATG5 complex in both types of
cells overexpressing a-synuclein compared to controls
(Figure 3C). Such an increase is not due to transfection
reagent exposure, given the presence of ATG8/LC3-II in
control SH-SY5Y cells (Figure 3C). LC3-II (phosphatidyl
ethanolamine-modified form of LC3) is stably associated
with autophagosomal membranes and is therefore con-
sidered an autophagy-specific marker [20]. In addition
to the full length 60kDa ATG6/Beclin 1 [21], its 50kDa
cleavage proteolytic fragment appears in all three groups
of cells. There is no significant difference between the
observable levels of LC3-II and ATG/Beclin 1 in cells
transfected with different a-synuclein plasmids and
controls.
Discussion
We observed increased a-synuclein-immunoreactive
neurites in PD cases with A53T mutations, as pre-
viously described [22]. Clinically, these cases have an
earlier onset and shorter disease duration compared to
sporadic PD. These changes are also seen in mice
expressing A53T mutant a-synuclein but not WT a-
synuclein, as the mutant-expressing mice develop age-
dependent intracytoplasmic neuronal a-synuclein
inclusions and severe motor impairment [23]. Our cell
culture data showed reduced cell viability of the A53T
a-synuclein mutant expressing cells compared to those
with WT a-synuclein expression, consistent with pre-
vious reports [24]. We also observed a significant
increase in the numbers of a-synuclein-immunoreac-
tive aggregates in A53T compared to WT a-synuclein
transfected SH-SY5Y cells, as previously described
[24]. These data support previous findings that A53T
mutant a-synuclein aggregates more rapidly in neu-
rons, is degraded more slowly and has greater toxicity
than WT a-synuclein [25]. Intracellular a-synuclein
aggregation can be due to an increase in its expression,
such as observed in cases of a-synuclein gene multipli-
cation [4], or a decrease in its clearance through
Figure 1 a-Synuclein immunohistochemistry in PD. Although both sporadic cases and those with A53T a-synuclein mutations had severe
neuronal loss in the substantia nigra, substantially more a-synuclein positive neurites and dots were seen in the A53T cases (A) compared with
sporadic PD (B). As expected, there were more a-synuclein-immunopositive Lewy body and astrocytes in the cortex of end-stage (C) versus
earlier stages of PD (D).
Huang et al. Translational Neurodegeneration 2012, 1:2
http://www.translationalneurodegeneration.com/content/1/1/2
Page 4 of 7
Archived at Flinders University: dspace.flinders.edu.au
autophagic pathways [26-30]. Autophagy is an evolu-
tionarily conserved process by which eukaryotic cells
regulate the turnover of long-lived proteins and cyto-
plasmic organelles. As described in the introduction,
there are three types of autophagy: macroautophagy,
microautophagy and chaperone-mediated autophagy
(CMA). WT, but not A53T mutant, a-synuclein is
degraded through the CMA pathway [11]. However,
A53T mutant or other modifications to WT a-synu-
clein, or the overexpression of WT a-synuclein, leads
to CMA dysfunction in neurons, and this in turn leads
to a compensatory induction of macroautophagy
[31-33]. Therefore, we investigated changes in macro-
autophagy markers in PD patients with the A53T
mutation and sporadic PD, and appropriate cell
models.
We observed elevated expression of macroautophagy
markers in cells overexpressing either WT or A53T
mutant a-synuclein, and there was no significant
difference in macroautophagy expression between cells
transfected with WT or mutant a-synuclein, suggesting a
compensatory induction of macroautophagy [31-33]. The
induction of macroautophagy was not further enhanced
by the more toxic A53T species of a-synuclein. Our study
is the first to show that cellular a-synuclein overexpres-
sion significantly elevates the levels of the ATG5 complex,
regardless of whether WT or mutant a-synuclein is
expressed, consistent with enhanced macroautophagy.
This contrasts with recent findings of a reduction in
ATG8/LC3-II in WT a-synuclein transfected cells but not
in A53T mutant a-synuclein transfected cells [34]. After
standardising for the number of cells transfected, our data
show only subtle changes at best between WT and A53T
mutant a-synuclein transfected cells using a greater num-
ber of macroautophagy markers, findings consistent with
our observations in PD brain tissue.
We observed an increase in ATG8/LC3-immunoposi-
tive cortical neurons in late-stage PD, consistent with
Figure 2 Macroautophagy marker immunohistochemistry in PD. (A) ATG8/LC3-immunopositive cells were observed in both end-stage
sporadic PD as well as in cases with A53T mutations where a-synuclein accumulations are found in the cortex, and were not observed in earlier
PD stages or in controls (B) where there is an absence of cortical a-synuclein accumulation. In isolated Lewy bodies identified with a-synuclein
antibodies (C, D), there was no ATG8/LC3immunoreactivity.
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previous findings in dementia with Lewy bodies [15,35].
We are the first group to investigate macroautophagy
markers in PD cases with A53T mutations compared to
sporadic PD. We observed no differences between the
relative densities of ATG8/LC3-immunopositive neurons
in end-stage sporadic PD cases and those with A53T
mutations, despite greater densities of a-synuclein accu-
mulations in the A53T mutation cases. These data show
that macroautophagy is induced in association with a-
synuclein aggregation, but this increase does not appear
to be directly related to its WT or mutant forms.
Our data also show that macroautophagy markers do
not co-localise with the large a-synuclein aggregates
either in brain tissue or cultured cells. Their pattern of
staining is more reminiscent of organelle macroauto-
phagy. Macroautophagy of mitochondria (mitophagy) is
now thought to be a significant contributor to many dif-
ferent forms of PD, including patients with mutations in
PINK-1, parkin and most recently PARL [36,37]. In
addition, cell culture models show that mutant A53T a-
synuclein induces mitophagy [16] and that increased
WT a-synuclein impairs mitochondrial function inde-
pendently of cellular a-synuclein aggregation [38]. The
cellular aggregation of a-synuclein has recently been
linked to cytoprotective changes associated with
decreased mitochondrial calcium [39]. These data are
consistent with our findings that macroautophagy mar-
kers do not routinely engulf or accumulate with insolu-
ble intracellular a-synuclein, possibly indicating a more
important role for macroautophay in mitophagy in PD
rather than in a-synuclein aggregate disposal. Overall,
our data show a similar increase in the levels of macro-
autophagy in both sporadic PD and in cases with more
toxic A53T mutations.
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